Dyne Therapeutics (DYN) Shares Outstanding (2019 - 2026)

Dyne Therapeutics (DYN) has reported Shares Outstanding (Entity) for 8 consecutive years, with $165.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Shares Outstanding (Entity) rose 44.89% year-over-year to $165.7 million; the TTM figure through Jun 2026 stood at $165.7 million (up 44.89% YoY), while the FY2025 annual figure was $128.4 million, up 25.53% from the prior year.
• Shares Outstanding (Entity) held at $165.7 million in Q2 2026 per DYN's latest filing, from $165.2 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $165.7 million in Q2 2026 and bottomed at $51.7 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $93.0 million across 5 years, with a median of $93.6 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) grew 0.41% — and 2024, when it surged 66.46%.
• Dyne Therapeutics' Shares Outstanding (Entity) stood at $55.6 million in 2022, then grew by 10.48% to $61.5 million in 2023, then soared by 66.46% to $102.3 million in 2024, then grew by 25.53% to $128.4 million in 2025, then rose by 28.98% to $165.7 million in 2026.
• Business Quant data shows DYN's Shares Outstanding (Entity) at $165.7 million in Q2 2026, $165.2 million in Q1 2026, and $128.4 million in Q4 2025.